Trustmark National Bank Trust Department held its position in Astrazeneca PLC (NYSE:AZN) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,445 shares of the company’s stock at the end of the 2nd quarter. Trustmark National Bank Trust Department’s holdings in Astrazeneca PLC were worth $424,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ativo Capital Management LLC purchased a new stake in shares of Astrazeneca PLC in the second quarter valued at $269,000. PNC Financial Services Group Inc. lifted its holdings in shares of Astrazeneca PLC by 8.1% in the second quarter. PNC Financial Services Group Inc. now owns 221,371 shares of the company’s stock valued at $7,546,000 after purchasing an additional 16,548 shares in the last quarter. Nationwide Fund Advisors lifted its holdings in shares of Astrazeneca PLC by 1.7% in the second quarter. Nationwide Fund Advisors now owns 52,400 shares of the company’s stock valued at $1,786,000 after purchasing an additional 900 shares in the last quarter. Affinity Wealth Management purchased a new stake in shares of Astrazeneca PLC in the second quarter valued at $204,000. Finally, Comerica Securities Inc. lifted its holdings in shares of Astrazeneca PLC by 22.9% in the second quarter. Comerica Securities Inc. now owns 14,369 shares of the company’s stock valued at $490,000 after purchasing an additional 2,681 shares in the last quarter. Institutional investors own 14.17% of the company’s stock.
A number of analysts have recently issued reports on AZN shares. Zacks Investment Research lowered Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a report on Monday, July 17th. Natixis upgraded Astrazeneca PLC from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. BidaskClub lowered Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. Finally, Cowen and Company restated a “hold” rating and issued a $34.00 target price on shares of Astrazeneca PLC in a report on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $33.60.
Astrazeneca PLC (NYSE AZN) traded up 0.291% during trading on Wednesday, reaching $32.765. 2,050,428 shares of the company’s stock traded hands. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The firm has a market cap of $82.96 billion, a PE ratio of 21.492 and a beta of 0.74. The firm has a 50 day moving average price of $30.33 and a 200-day moving average price of $31.81.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same period in the previous year, the business earned $0.83 EPS. The company’s revenue was down 9.9% compared to the same quarter last year. On average, analysts forecast that Astrazeneca PLC will post $1.90 earnings per share for the current fiscal year.
The firm also recently declared a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were paid a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 9th. This represents a yield of 2.98%. Astrazeneca PLC’s payout ratio is currently 44.92%.
COPYRIGHT VIOLATION NOTICE: “Trustmark National Bank Trust Department Has $424,000 Position in Astrazeneca PLC (AZN)” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/20/trustmark-national-bank-trust-department-has-424000-position-in-astrazeneca-plc-azn.html.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.